<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.114289</article-id><article-id pub-id-type="publisher-id">ACM-42049</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210400000_92948903.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  富血小板血浆治疗足底筋膜炎的随机对照实验Meta分析
  Treatment of Plantar Fasciitis with Platelet-Rich Plasma: A Meta-Analysis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>黄</surname><given-names>琬云</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>朱</surname><given-names>嘉卉</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>姜</surname><given-names>影</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>肖</surname><given-names>晓飞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>孝刚</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>滨州医学院康复医学院，山东 烟台</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>04</month><year>2021</year></pub-date><volume>11</volume><issue>04</issue><fpage>1373</fpage><lpage>1382</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：系统评价富血小板血浆(PRP)治疗足底筋膜炎的有效性。方法：利用互联网技术来检索CNKI、Wangfang Data、Pubmed、Ebsco、Pedro和Cochrane Library，查找一些使用PRP和类固醇等激素注射治疗足底筋膜炎的相关资料，检索时间为近五年，截至2021年4月。按照制订的纳入排除标准筛选文章并进行文献质量评价，同时进行仔细甄别经筛选的各篇文章，并合理地对其内容进行了相关文献的综合质量指标评估，且应用了Rev Man5.3软件进行Meta分析。结果：本Meta分析最终纳入6项研究，共397名患者。Meta结果分析表明，3个月内，类固醇联合组缓解足部疼痛及改善脚踝等脚趾足部肌肉运动生理功能的效果优于PRP组(P &lt; 0.05)；而在6个月后，PRP组在帮助治疗慢性疼痛和帮助增强脚踝足部肌肉活动等生理功能时的效果显著程度优于其他两种类固醇治疗组，效果的明显差别也均具有重要统计学事实意义(P &lt; 0.05)；在3个月内和6个月后，PRP组在足底筋膜厚度的改善率上明显优于其他类固醇组，效果的差别具有统计学意义(P &lt; 0.05)。结论：类固醇激素治疗对于短期内疼痛减轻及其功能提升优于PRP，但是对于远期疼痛减轻及其功能提升，PRP具有明显的优势。由于此次纳入研究的相关文献及实验数据资料较少且存在着较大的异质性，因此我们需要从中获取到更多高质量的临床研究证据。
   Objective: To evaluate the efficacy of platelet rich plasma (PRP) in the treatment of plantar fasciitis. Methods: The method is to search CNKI, Wangfang data, PubMed, EBSCO, Pedro and Cochrane Library by using Internet technology to find some relevant information about the treatment of plantar fasciitis with hormone injection such as PRP and steroids. The search time is nearly five years, up to April 2021. According to the selected criteria which are listed as exclusion factors, the article is screened, and the quality of the literature is reasonably evaluated. Revman 5.3 software was used for meta-analysis. Results: Six randomized controlled trials with 397 subjects were selected. Meta analysis showed that, within 3 months, the efficacy of steroid group in treating foot pain and improving foot movement function such as ankle was significantly better than that of PRP group (P &lt; 0.05); after 6 months, PRP group was significantly better than other steroid groups in treating chronic pain and enhancing foot movement function (P &lt; 0.05); within 3 months and 6 months, the improvement rate of plantar fascia thickness in PRP group was significantly better than that in other steroid groups, and the difference was statistically significant (P &lt; 0.05). Conclusion: Steroid therapy is superior to PRP in short-term pain relief and function improvement, but PRP has obvious advantages in long-term pain relief and function improvement. Due to the lack of relevant literature and experimental data, we need to obtain more high-quality clinical research evidence.
 
</p></abstract><kwd-group><kwd>足底筋膜炎，富血小板血浆，疼痛，Meta分析, Plantar Fasciitis</kwd><kwd> Platelet-Rich Plasma</kwd><kwd> Pain</kwd><kwd> Meta-Analysis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：系统评价富血小板血浆(PRP)治疗足底筋膜炎的有效性。方法：利用互联网技术来检索CNKI、Wangfang Data、Pubmed、Ebsco、Pedro和Cochrane Library，查找一些使用PRP和类固醇等激素注射治疗足底筋膜炎的相关资料，检索时间为近五年，截至2021年4月。按照制订的纳入排除标准筛选文章并进行文献质量评价，同时进行仔细甄别经筛选的各篇文章，并合理地对其内容进行了相关文献的综合质量指标评估，且应用了Rev Man5.3软件进行Meta分析。结果：本Meta分析最终纳入6项研究，共397名患者。Meta结果分析表明，3个月内，类固醇联合组缓解足部疼痛及改善脚踝等脚趾足部肌肉运动生理功能的效果优于PRP组(P &lt; 0.05)；而在6个月后，PRP组在帮助治疗慢性疼痛和帮助增强脚踝足部肌肉活动等生理功能时的效果显著程度优于其他两种类固醇治疗组，效果的明显差别也均具有重要统计学事实意义(P &lt; 0.05)；在3个月内和6个月后，PRP组在足底筋膜厚度的改善率上明显优于其他类固醇组，效果的差别具有统计学意义(P &lt; 0.05)。结论：类固醇激素治疗对于短期内疼痛减轻及其功能提升优于PRP，但是对于远期疼痛减轻及其功能提升，PRP具有明显的优势。由于此次纳入研究的相关文献及实验数据资料较少且存在着较大的异质性，因此我们需要从中获取到更多高质量的临床研究证据。</p></sec><sec id="s2"><title>关键词</title><p>足底筋膜炎，富血小板血浆，疼痛，Meta分析</p></sec><sec id="s3"><title>Treatment of Plantar Fasciitis with Platelet-Rich Plasma: A Meta-Analysis</title><p>Wanyun Huang, Jiahui Zhu<sup>*</sup>, Ying Jiang, Xiaofei Xiao, Xiaogang Zhang</p><p>School of Rehabilitation Medicine, Binzhou Medical University, Yantai Shandong</p><p><img src="//html.hanspub.org/file/82-1572188x5_hanspub.png" /></p><p>Received: Mar. 27<sup>th</sup>, 2021; accepted: Apr. 21<sup>st</sup>, 2021; published: Apr. 29<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/82-1572188x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To evaluate the efficacy of platelet rich plasma (PRP) in the treatment of plantar fasciitis. Methods: The method is to search CNKI, Wangfang data, PubMed, EBSCO, Pedro and Cochrane Library by using Internet technology to find some relevant information about the treatment of plantar fasciitis with hormone injection such as PRP and steroids. The search time is nearly five years, up to April 2021. According to the selected criteria which are listed as exclusion factors, the article is screened, and the quality of the literature is reasonably evaluated. Revman 5.3 software was used for meta-analysis. Results: Six randomized controlled trials with 397 subjects were selected. Meta analysis showed that, within 3 months, the efficacy of steroid group in treating foot pain and improving foot movement function such as ankle was significantly better than that of PRP group (P &lt; 0.05); after 6 months, PRP group was significantly better than other steroid groups in treating chronic pain and enhancing foot movement function (P &lt; 0.05); within 3 months and 6 months, the improvement rate of plantar fascia thickness in PRP group was significantly better than that in other steroid groups, and the difference was statistically significant (P &lt; 0.05). Conclusion: Steroid therapy is superior to PRP in short-term pain relief and function improvement, but PRP has obvious advantages in long-term pain relief and function improvement. Due to the lack of relevant literature and experimental data, we need to obtain more high-quality clinical research evidence.</p><p>Keywords:Plantar Fasciitis, Platelet-Rich Plasma, Pain, Meta-Analysis</p><disp-formula id="hanspub.42049-formula213"><graphic xlink:href="//html.hanspub.org/file/82-1572188x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/82-1572188x8_hanspub.png" /> <img src="//html.hanspub.org/file/82-1572188x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>足底筋膜炎(plantar fasciitis)的主要临床表现为关节足跟疼痛，是一种慢性骨质退行性病，是影响人体下肢运动功能最常见的足踝矫形外科疾病之一 [<xref ref-type="bibr" rid="hanspub.42049-ref1">1</xref>]。成年人的足底筋膜炎各年龄段的发病率为30~40岁(22%)、41~50岁(36%)、51~60岁(32%)、61~70岁(2%)、大于70岁(8%) [<xref ref-type="bibr" rid="hanspub.42049-ref2">2</xref>]，尤其是运动员、女性及肥胖者更为多见，常表现在舞蹈家、网球运动员、篮球运动员以及职业上需要持久负重的运动员身上 [<xref ref-type="bibr" rid="hanspub.42049-ref3">3</xref>]。根据美国的流行病学报告，发病率大约为0.5%左右，在经常进行体育运动的人群中会高达10%左右 [<xref ref-type="bibr" rid="hanspub.42049-ref4">4</xref>]。主要危险影响因素有：穿不正确合适的鞋子，过度长期站立，突然性体重减轻，突然强迫运动例如大量行走或者是跑步、踝关节的背屈力受限、扁平足、过度转身旋前、足内侧翻在肌肉运动能力薄弱及下肢运动灵活性较低等 [<xref ref-type="bibr" rid="hanspub.42049-ref5">5</xref>]。主要临床表现为晨起下床或休息后起步时足跟疼痛加重 [<xref ref-type="bibr" rid="hanspub.42049-ref6">6</xref>]。</p><p>足底筋膜炎的保守治疗措施方法很多，如腓肠肌牵伸、非甾体类抗炎药物的注射、局部类固醇和其他激素的注射、使用脚跟垫、足弓支撑、夜间支具的固定、电疗、自体血液的注射、富血小板血浆的注射及体外冲击波的治疗等，但是目前这些治疗方法都没有得到很好的证据支持。有一些学者认为治疗方法应从拉伸足底筋膜，冰按摩和非甾体类抗炎药物治疗开始 [<xref ref-type="bibr" rid="hanspub.42049-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.42049-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.42049-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.42049-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.42049-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.42049-ref10">10</xref>]。根据目前相关研究显示，反复的皮质类固醇类的注射在多个研究中发现容易导致足底筋膜变脆弱后发生断裂 [<xref ref-type="bibr" rid="hanspub.42049-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.42049-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.42049-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.42049-ref14">14</xref>]。</p><p>富含血小板的血浆(PRP)作为一种理想的自体生物血液衍生产品近年来得到推广，该产品可以外源性地适用于各种组织，可释放高浓度的血小板源性生长因子，从而增强伤口、骨骼和肌腱的愈合 [<xref ref-type="bibr" rid="hanspub.42049-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.42049-ref16">16</xref>]。在动物中，向断裂的肌腱添加生长因子已显示出可增强肌腱的愈合效果 [<xref ref-type="bibr" rid="hanspub.42049-ref17">17</xref>]。在人类中，已经证明将血小板注入肌腱可有效减轻疼痛 [<xref ref-type="bibr" rid="hanspub.42049-ref12">12</xref>]。</p><p>目前，国内外关于将PRP 应用到足底筋膜炎治疗的研究工作人员总数正在逐年上升，所得到的实验数据也越来越多，但是关于PRP应用到足底筋膜炎治疗的临床仍然缺少一些可行的循证医学依据。本课题研究会系统地评价PRP在治疗足底筋膜炎中的安全性与有效率，目的是为临床上治疗足底筋膜炎的诊断提供了一个参考。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 文献检索与策略</title><p>以电脑检索和人工检查为主，以网络检索和电子邮件为辅。电脑检索CNKI、Wangfang Data、Pubmed、Ebsco、Pedro和Cochrane Library，查找使用PRP和类固醇类激素注射治疗足底筋膜炎的相关文献。中文的检索单词分别为“足底筋膜炎”、“富血小板血浆”，英文的检索单词分别为“plantar fasciitis”，“plantar fasciopathy”，“plantlet-rich plasma”，“PRP”。检索日期为近10年，截止至2020年8月。以PubMed为例，具体检索策略如下：</p><p>1# plantar fasciitis OR plantar fasciopathy OR heel pain</p><p>2# platelet-rich plasma OR PRP</p><p>3# randomized control trail OR RCT</p><p>4#1# AND 2# AND 3#</p></sec><sec id="s6_2"><title>2.2. 纳入标准</title><p>纳入临床研究的试验类型：① 内科临床随机对照诊断试验(RCTs)；纳入研究调查对象为：a) 具有明确的临床诊断试验标准；b) 临床诊断为足底筋膜炎；c) 患者的名字出生日期年龄、性别、病程、疾案和其他病例相关信息数据来源等可能数量不限；② 其他临床干预治疗措施：临床试验组患者可以通过富含性血小板注射血浆(PRP)治疗方式对其进行血液检测和注射治疗，对照组患者可以通过注射类固醇或其他神经激素治疗方式对其进行滴液静脉注射(CS)；③ 结局结果评价质量指标：至少一组应该提供包括所有的隐含疼痛的样品视觉影像仿真结果评价的质量参数表(visualanaloguescale, vas)、足底筋膜厚度和AOFAS踝-后足评分系统等其中一项。</p></sec><sec id="s6_3"><title>2.3. 排除标准</title><p>非临床随机对照试验；疗效结果不完整或不明确的文献；重复的文献；无法获取全文的文献；综述、系统评价、动物实验等。</p></sec><sec id="s6_4"><title>2.4. 文献筛选</title><p>由两名独立的学者根据已经制定的文件检索策略、纳入和排除的标准等对文件进行了筛选，通过仔细阅读所搜寻到的文件题目和摘要，甄别得出与之相符合的文献后，进一步对整个文献全部内容进行了通读，最终确定纳入分析的研究。</p></sec><sec id="s6_5"><title>2.5. 数据提取</title><p>对其中被纳入的研究可以提取如下几个数据：病人基本情况信息、干预措施和治疗结局等指标。数据的提取工作全过程由2名研究者单独进行并且交叉审查核对，如果在工作中遇到不一致性的文献最终由第3名研究者作出判断。</p></sec><sec id="s6_6"><title>2.6. 文献质量评价</title><p>最终被批准纳入的课题研究结果文献报表可以作为参考：Cochrane Handbook5.1.0版本的评估标准对该研究文献结果进行了报表质量综合评估，由2名不同专业的课题研究者共同作为一个单独成员组成调查小组，进行了研究文献报表质量的综合评估，该质量评估的调查内容主要范围包括随机分析序列的基本产生、盲法、分配法的隐蔽、结果分析资料的基本完整性、选择性分析报表以及其它的价值偏倚等，质量综合评估标准可以明确划分表现为3个基本层次：“低风险”、“不明确”和“高风险”。</p></sec><sec id="s6_7"><title>2.7. 统计学方法</title><p>本文的实验研究结果主要选择的是使用Rev Man5.3软件对实验计量到的数据资料分别进行Meta的数据分析，计数到的数据资料和具体实验测量到的数据资料分别以相对值和加权值的危险度(risk ratio RR)和相对应的加权非线性平均数差(weighted mean difference, WMD)两个函数给出来分别作为区间代表，均以95%的可信度依赖度作为区间(confidence interval, CI)。所有被选择的纳入检验研究的异质性纳入检验都必须是通过通q纳入检验及通过I<sup>2</sup>分析方法的检验来进行组合和计算的方式才能进行，若各被选的纳入检验研究之间均不具有任何其他统计学异质性(I<sup>2</sup> ≤ 50%，P ≥ 0.10)，通过对所纳入采用的随机固定化学效应分析模型的所有异质性结果进行综合分析；如果各种化学原因从被纳入研究到两个相应的纳入研究之间后都具有一定的任何统计学异质性(I<sup>2</sup> &gt; 50%，P &lt; 0.10)，则我们可以通过考虑选择通过采用敏感性综合分析或者通过亚组合性分析方法组合来作为查找其异质性的主要数据分析来源，采用随机固定效应分析模型对其结果进行Meta综合分析。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 文献筛选流程及结果</title><p>计算机数字检索文献数据库共累计查获收录文献94篇，经过过去再多次考核后找出剩余的收录文献59篇，再经过仔细审核阅读了每篇文献的主要研究课题、摘要和文献原文，最终将其全部纳入经过定量</p><p>图1. 文献筛选流程及结果</p><p>数据综合分析合成的收录文献共6篇 [<xref ref-type="bibr" rid="hanspub.42049-ref18">18</xref>] - [<xref ref-type="bibr" rid="hanspub.42049-ref23">23</xref>]，见图1。</p></sec><sec id="s7_2"><title>3.2. 纳入研究的基本特征</title><p>最终6篇文献 [<xref ref-type="bibr" rid="hanspub.42049-ref18">18</xref>] - [<xref ref-type="bibr" rid="hanspub.42049-ref23">23</xref>] 被纳入研究，涉及397例病人的患者，纳入研究文献分别为1篇中文和5篇英文文献。所纳入研究中外国人的研究居多，受试者的年龄均超过18周岁，随访时间一般为1~12个月，试验组的干预措施分别为注射不同计量的PRP，对照组的干预措施分别为类固醇类激素注射，包括：甲泼尼龙、贝他米松、甲强龙、曲安奈德等。结局性指标主要包括VAS、足底筋膜厚度以及AOFAS评分，纳入研究基本特点见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Basic characteristics of the included studie</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >第一作者</th><th align="center" valign="middle"  rowspan="2"  >国家</th><th align="center" valign="middle"  rowspan="2"  >发表 时间</th><th align="center" valign="middle"  rowspan="2"  >病例数 (PRP/CS)</th><th align="center" valign="middle"  rowspan="2"  >年龄 (PRP/CS)</th><th align="center" valign="middle"  rowspan="2"  >男/女</th><th align="center" valign="middle"  rowspan="2"  >随访 时间</th><th align="center" valign="middle"  colspan="2"  >干预措施</th><th align="center" valign="middle"  rowspan="2"  >结局指标</th></tr></thead><tr><td align="center" valign="middle" >PRP</td><td align="center" valign="middle" >CS</td></tr><tr><td align="center" valign="middle" >Ankit Khurana [<xref ref-type="bibr" rid="hanspub.42049-ref23">23</xref>]</td><td align="center" valign="middle" >印度</td><td align="center" valign="middle" >2020</td><td align="center" valign="middle" >58/60</td><td align="center" valign="middle" >(32.57 &#177; 4.98)/ (34.70 &#177; 5.46)</td><td align="center" valign="middle" >68/50</td><td align="center" valign="middle" >6个月</td><td align="center" valign="middle" >2 ml PRP</td><td align="center" valign="middle" >2 ml德普麦洛</td><td align="center" valign="middle" >①③</td></tr><tr><td align="center" valign="middle" >Soraganvi P [<xref ref-type="bibr" rid="hanspub.42049-ref22">22</xref>]</td><td align="center" valign="middle" >印度</td><td align="center" valign="middle" >2019</td><td align="center" valign="middle" >29/28</td><td align="center" valign="middle" >(40.27 &#177; 8.03)/ (39.35 &#177; 12.5)</td><td align="center" valign="middle" >26/31</td><td align="center" valign="middle" >6个月</td><td align="center" valign="middle" >3 ml PRP</td><td align="center" valign="middle" >2 ml甲泼尼松</td><td align="center" valign="middle" >②③</td></tr><tr><td align="center" valign="middle" >程浩 [<xref ref-type="bibr" rid="hanspub.42049-ref18">18</xref>]</td><td align="center" valign="middle" >中国</td><td align="center" valign="middle" >2018</td><td align="center" valign="middle" >16/16</td><td align="center" valign="middle" >(54.6 &#177; 8.6)/ (53.3 &#177; 9.5)</td><td align="center" valign="middle" >9/23</td><td align="center" valign="middle" >6个月</td><td align="center" valign="middle" >1 ml PRP</td><td align="center" valign="middle" >4 ml贝他米松</td><td align="center" valign="middle" >①②</td></tr><tr><td align="center" valign="middle" >Sumit Kumar Jain [<xref ref-type="bibr" rid="hanspub.42049-ref20">20</xref>]</td><td align="center" valign="middle" >印度</td><td align="center" valign="middle" >2018</td><td align="center" valign="middle" >40/40</td><td align="center" valign="middle" >(37.7 &#177; 10.3)/ (38.9 &#177; 9.5)</td><td align="center" valign="middle" >46/34</td><td align="center" valign="middle" >6个月</td><td align="center" valign="middle" >3 ml PRP</td><td align="center" valign="middle" >2 ml甲强龙</td><td align="center" valign="middle" >① ②③</td></tr><tr><td align="center" valign="middle" >Mahindra P [<xref ref-type="bibr" rid="hanspub.42049-ref19">19</xref>]</td><td align="center" valign="middle" >印度</td><td align="center" valign="middle" >2016</td><td align="center" valign="middle" >25/25</td><td align="center" valign="middle" >(30.72 &#177; 7.42)/ (33.92 &#177; 8.61)</td><td align="center" valign="middle" >20/30</td><td align="center" valign="middle" >3个月</td><td align="center" valign="middle" >2.5~3 ml PRP</td><td align="center" valign="middle" >2 ml甲泼尼松</td><td align="center" valign="middle" >①③</td></tr><tr><td align="center" valign="middle" >Kowshik Jain [<xref ref-type="bibr" rid="hanspub.42049-ref21">21</xref>]</td><td align="center" valign="middle" >英国</td><td align="center" valign="middle" >2015</td><td align="center" valign="middle" >30/30</td><td align="center" valign="middle" >55.6</td><td align="center" valign="middle" >16/30</td><td align="center" valign="middle" >12个月</td><td align="center" valign="middle" >3 ml PRP</td><td align="center" valign="middle" >3 ml泼尼松龙</td><td align="center" valign="middle" >①③</td></tr></tbody></table></table-wrap><p>表1. 纳入研究的基本特征</p><p>PRP：试验组为富血小板血浆注射治疗CS：对照组为类固醇类激素注射治疗① VAS ②足底筋膜厚度③ AOFA (American Orthopedic Foot and Ankle Society)。</p></sec><sec id="s7_3"><title>3.3. 文献质量评价</title><p>纳入这一课题的6项研究都已经明确地提到了随机分组，其中5篇 [<xref ref-type="bibr" rid="hanspub.42049-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.42049-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.42049-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.42049-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.42049-ref23">23</xref>] 通过移动互联网技术系统制造和生成随机分组，其余均没有明确地说明如何制造随机分组方法。纳入的研究中只有2个 [<xref ref-type="bibr" rid="hanspub.42049-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.42049-ref22">22</xref>] 提供了较为具体的对于分配和隐藏进行实施的方法，1个研究则主要是在盲法上提供了一个具体的研究者和受试人员的对于盲法进行实施，其余部分的研究没有具体地提及他们是否已经使用过了分配和隐藏以及盲法；其中已经有2项被纳入 [<xref ref-type="bibr" rid="hanspub.42049-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.42049-ref22">22</xref>] 的研究为我们提供了细致地分配和隐藏的方法，1项被纳入 [<xref ref-type="bibr" rid="hanspub.42049-ref22">22</xref>] 则具体地详细描述了如何利用分配盲法在实际工作中的应用，其余研究没有明确地提及如何正确采用分配隐藏以及如何正确地使用分配盲法；受试者的随访中退出或遗漏等情况，只有在1项研究 [<xref ref-type="bibr" rid="hanspub.42049-ref22">22</xref>] 中被明确提及；这种选择性的偏倚与其它的偏倚现象在所有纳入到的研究中都并不明确。纳入本次研究的偏倚性风险评价情况详见图2。</p></sec><sec id="s7_4"><title>3.4. Meta分析结果</title><sec id="s7_4_1"><title>3.4.1. 疼痛的改善程度</title><p>纳入研究中，有4项研究 [<xref ref-type="bibr" rid="hanspub.42049-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.42049-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.42049-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.42049-ref23">23</xref>] 对患者的疼痛治疗和改善情况的影响程度进行了综合评价，Meta分析结果显示，在短期(治疗后3个月内) [WMD =1.28; 95%; CI(0.96, 1.59); P &lt; 00001]，结合森林地理图中SMD值与95% CI值，菱形区域位于无效治疗路径右侧，类固醇激素注射治疗组在缓解疼痛症状方面明显优于PRP治疗组(参见图3)；在远期(接受治疗后6个月) [WMD = −1.66; 95%; CI (−1.66, −1.10); P &lt; 00001]，结合森林地理图中SMD值与95% CI值，菱形区域位于治疗组无效光谱线左侧，PRP治疗组在缓解痛苦方面的疗效明显优于类固醇激素治疗组(参见图4)。</p><p>图2. 纳入研究偏倚风险评估</p><p>图3. 两组治疗后短期(3个月内)疼痛改善程度比较的Meta分析</p><p>图4. 两组治疗后远期(6个月后)疼痛改善程度比较的Meta分析</p></sec><sec id="s7_4_2"><title>3.4.2. 足底筋膜厚度的改变</title><p>纳入的研究中，有2项研究 [<xref ref-type="bibr" rid="hanspub.42049-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.42049-ref22">22</xref>] 对远期受试者足底筋膜厚度情况进行了评价，Meta分析结果显示，在远期(接受治疗后6个月) [WMD = −0.35; 95% CI (−0.53, −0.17); P = 0.0002]，结合森林地图中SMD值与95% CI的值，菱形位于无效线的左侧，PRP治疗组在缓解疼痛方面的效果优于类固醇激素治疗组(图5)。</p><p>图5. 两组治疗后远期(6个月后)足底筋膜厚度改变比较的Meta分析</p></sec><sec id="s7_4_3"><title>3.4.3. AOFAS评分的改变</title><p>纳入的研究中，有5项研究 [<xref ref-type="bibr" rid="hanspub.42049-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.42049-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.42049-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.42049-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.42049-ref23">23</xref>] 对每一个受试者的AOFAS情况进行了综合评价，Meta分析的结果表明，在短期(治疗后3个月内) [WMD = −6.44; 95% CI (−7.71, −5.18); P &lt; 00001]，结合森林地理图中SMD值与95% CI值，菱形区域位于无效治疗路径左侧，类固醇激素注射治疗在预防和缓解疼痛症状方面明显优于PRP治疗组(参见图6)；在远期(接受治疗后6个月) [WMD = 6.23; 95% CI (5.24, 7.21); P &lt; 00001]，结合森林地理图中SMD值与95% CI值，菱形坐标点位于无效线的右侧，PRP治疗组在缓解疼痛方面的效果优于类固醇激素治疗组(图7)。</p><p>图6. 两组治疗后短期(3个月内)AOFAS评分比较的Meta分析</p></sec></sec></sec><sec id="s8"><title>4. 讨论</title><p>足底筋膜炎的典型表现是足底部内侧的疼痛，尤其是清晨起床下地活动时尤为明显，其临床表现严重影响到患者的运动功能 [<xref ref-type="bibr" rid="hanspub.42049-ref20">20</xref>]。部分学者认为，局部类固醇激素的注射和药物治疗可以在短时间内有效地</p><p>图7. 两组治疗后远期(6个月后) AOFAS评分比较的Meta分析</p><p>缓解病人的疼痛而且具有一定作用的减轻和促进心理健康 [<xref ref-type="bibr" rid="hanspub.42049-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.42049-ref14">14</xref>]，但是类固醇类激素的注射治疗易导致复发并且远期结局并不乐观 [<xref ref-type="bibr" rid="hanspub.42049-ref24">24</xref>]。近年来，越来越多的研究开始关注在替代疗法上如：富血小板血浆治疗等。也有研究表明富血小板血浆治疗足底筋膜炎能长时间的改善疼痛并提高患者功能 [<xref ref-type="bibr" rid="hanspub.42049-ref25">25</xref>]。然而目前并没有充足的证据证明富血小板血浆在疼痛缓解和功能改善方面明显优于类固醇类激素的治疗 [<xref ref-type="bibr" rid="hanspub.42049-ref26">26</xref>]。因此，本次研究的主要目标就是为了比较治疗患者在疼痛的缓解及其功能的改善等方面对富血小板人群的血浆治疗效果是否明显优于其他类固醇激素。</p><p>短时间(治疗后3个月内)类固醇激素注射治疗在缓解疼痛方面要优于PRP治疗组；在远期(治疗后6个月) PRP治疗组在缓解疼痛方面的效果优于类固醇激素治疗组；在足底筋膜厚度上，在远期(治疗后6个月) PRP治疗组在缓解疼痛方面的效果也优于类固醇激素治疗组；在AOFAS评分的治疗组，在短期(治疗后3个月内)类固醇激素注射治疗在缓解疼痛方面优于PRP治疗组，然而在远期(治疗后6个月) PRP治疗组在缓解疼痛方面的效果明显优于类固醇激素治疗组。</p><p>本课题研究仍然存在一定局限性，所纳入的研究仍然缺少一些质量相对较高的临床试验，虽然大多数被纳入的文献都曾经提及过随机化方法的特点和具体操作，但在对于分配方式的确定与否以及盲法的应用上并没有得到具体的说明，容易造成选择性的偏倚和执行性的偏倚问题出现。此外，本研究所要纳入的检测样本数量不够多，容易形成较低的检测效能。另外，通过本项目的研究可以发现，该领域的主要研究多数都集中在国外，大多数文献均来自国外，中国的随机临床试验甚少。因此我国学者应多致力于富血小板血浆的临床试验研究，为其提供更为可靠的临床证据。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，类固醇类激素治疗在短期内缓解足部疼痛及改善足部功能等方面明显优于富血小板血浆治疗；然而在远期的疼痛缓解及足部功能改善方面富血小板血浆仍然具有显著的治疗优势；在足底筋膜厚度的改善方面，富血小板血浆不论在短期还是远期来看都具有显著优势。</p></sec><sec id="s10"><title>基金项目</title><p>山东省自然科学基金资助项目(ZR2019BH069)。</p></sec><sec id="s11"><title>文章引用</title><p>黄琬云,朱嘉卉,姜 影,肖晓飞,张孝刚. 富血小板血浆治疗足底筋膜炎的随机对照实验Meta分析Treatment of Plantar Fasciitis with Platelet-Rich Plasma: A Meta-Analysis[J]. 临床医学进展, 2021, 11(04): 1373-1382. https://doi.org/10.12677/ACM.2021.114289</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42049-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Thompson, J.V., Saini, S.S., Reb, C.W. and Daniel, J.N. (2014) Diagnosis and Management of Plantar Fasciitis. Journal of the American Osteopathic Association, 114, 900-906. &lt;br&gt;https://doi.org/10.7556/jaoa.2014.177</mixed-citation></ref><ref id="hanspub.42049-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Riddle, D.L., Pulisic, M., Pidcoe, P. and Johnson, R.E. (2003) Risk Factors for Plantar Fasciitis: A Matched Case-Control Study. The Journal of Bone &amp; Joint Surgery, 85, 872-877.  
&lt;br&gt;https://doi.org/10.2106/00004623-200305000-00015</mixed-citation></ref><ref id="hanspub.42049-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Stecco, C., Corradin, M., Macchi, V., et al. (2013) Plantar Fascia Anatomy and Its Relationship with Achilles Tendon and Paratenon. Journal of Anatomy, 223, 665-676. &lt;br&gt;https://doi.org/10.1111/joa.12111</mixed-citation></ref><ref id="hanspub.42049-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Trojian, T. (2019) Plantar Fasciitis. American Family Physician, 99, 744-750.</mixed-citation></ref><ref id="hanspub.42049-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Irving, D.B., Cook, J.L., Young, M.A. and Menz, H.B. (2007) Obesity and Pronated Foot Type May Increase the Risk of Chronic Plantar Heel Pain: A Matched Case-Control Study. BMC Musculoskeletal Disorders, 8, Article No. 41.  
&lt;br&gt;https://doi.org/10.1186/1471-2474-8-41</mixed-citation></ref><ref id="hanspub.42049-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">焦睿，陈尚杰 余. 富血小板血浆对足底筋膜炎的疗效[J]. 广东医学, 2019, 40(19): 2759-2762.</mixed-citation></ref><ref id="hanspub.42049-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Martinelli, N., Marinozzi, A., Carnì, S., et al. (2012) Platelet-Rich Plasma Injections for Chronic Plantar Fasciitis. International Orthopaedics, 37, 839-842. &lt;br&gt;https://doi.org/10.1007/s00264-012-1741-0</mixed-citation></ref><ref id="hanspub.42049-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Porter, M.D. and Shadbolt, B. (2005) Intralesional Corticosteroid Injection versus Extracorporeal Shock Wave Therapy for Plantar Fasciopathy. Clinical Journal of Sport Medicine, 15, 119-124.  
&lt;br&gt;https://doi.org/10.1097/01.jsm.0000164039.91787.dc</mixed-citation></ref><ref id="hanspub.42049-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Dogramaci, Y., Kalaci, A., Emir, A., et al. (2009) Intracorporeal Pneumatic Shock Application for the Treatment of Chronic Plantar Fasciitis: A Randomized, Double Blind Prospective Clinical Trial. Archives of Orthopaedic and Trauma Surgery, 130, 541-546. &lt;br&gt;https://doi.org/10.1007/s00402-009-0947-0</mixed-citation></ref><ref id="hanspub.42049-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Buchbinder, R.P.R., Gordon, J., Buchanan, J., Prabaharan, V. and Forbes, A. (2002) Ultrasound-Guided Extracorporeal Shock Wave Therapy for Plantar Fasciitis: A Randomized Controlled Trial. JAMA, 288, 1364-1372.  
&lt;br&gt;https://doi.org/10.1001/jama.288.11.1364</mixed-citation></ref><ref id="hanspub.42049-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Acevedo, J. and Beskin, J. (1998) Complications of Plantar Fascia Rupture Associated with Corticosteroid Injection. Foot &amp; Ankle International, 19, 91-97. &lt;br&gt;https://doi.org/10.1177/107110079801900207</mixed-citation></ref><ref id="hanspub.42049-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Cole, C., Seto, C. and Gazewood, J. (2005) Plantar Fasciitis: Evidence-Based Review of Diagnosis and Therapy. American Family Physician, 72, 2237-2242.</mixed-citation></ref><ref id="hanspub.42049-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Leach, R., Jones, R. and Silva, T. (1978) Rupture of the Plantar Fascia in Athletes. The Journal of Bone &amp; Joint Surgery, 60, 537-539. &lt;br&gt;https://doi.org/10.2106/00004623-197860040-00018</mixed-citation></ref><ref id="hanspub.42049-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Sellman, J.R. (1994) Plantar Fascia Rupture Associated with Corticosteroid Injection. Foot &amp; Ankle International, 15, 376-381. &lt;br&gt;https://doi.org/10.1177/107110079401500706</mixed-citation></ref><ref id="hanspub.42049-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Engebretsen, L., Steffen, K., Alsousou, J., et al. (2010) IOC Consensus Paper on the Use of Platelet-Rich Plasma in Sports Medicine. British Journal of Sports Medicine, 44, 1072-1081. &lt;br&gt;https://doi.org/10.1136/bjsm.2010.079822</mixed-citation></ref><ref id="hanspub.42049-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Willits, K., Kaniki, N. and Bryant, D. (2013) The Use of Platelet-Rich Plasma in Orthopaedic Injuries. Sports Medicine and Arthroscopy Review, 21, 225-230. &lt;br&gt;https://doi.org/10.1097/JSA.0000000000000001</mixed-citation></ref><ref id="hanspub.42049-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Davies, M., Weiss, G. and Saxby, T. (1999) Plantar Fasciitis: How Successful Is Surgical Intervention? Foot &amp; Ankle International, 20, 803-807. &lt;br&gt;https://doi.org/10.1177/107110079902001209</mixed-citation></ref><ref id="hanspub.42049-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">程浩, 陆伟萍, 高献忠, 徐晨婕, 管华, 鲍红光. 超声引导下富血小板血浆注射治疗足底筋膜炎的疗效观察[J]. 临床麻醉学杂志, 2018, 34(11): 1072-1075.</mixed-citation></ref><ref id="hanspub.42049-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Mahindra, P., Yamin, M., Selhi, H.S., Singla, S. and Soni, A. (2016) Chronic Plantar Fasciitis: Effect of Platelet-Rich Plasma, Corticosteroid, and Placebo. Orthopedics, 39, e285-e289. &lt;br&gt;https://doi.org/10.3928/01477447-20160222-01</mixed-citation></ref><ref id="hanspub.42049-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Jain, S.K., Suprashant, K., Kumar, S., Yadav, A. and Kearns, S.R. (2018) Comparison of Plantar Fasciitis Injected with Platelet-Rich Plasma vs Corticosteroids. Foot &amp; Ankle International, 39, 780-786.  
&lt;br&gt;https://doi.org/10.1177/1071100718762406</mixed-citation></ref><ref id="hanspub.42049-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Jain, K., Murphy, P.N. and Clough, T.M. (2015) Platelet Rich Plasma versus Corticosteroid Injection for Plantar Fasciitis: A Comparative Study. The Foot, 25, 235-237. &lt;br&gt;https://doi.org/10.1016/j.foot.2015.08.006</mixed-citation></ref><ref id="hanspub.42049-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Soraganvi, P., Nagakiran, K.V., Raghavendra-Raju, R.P., et al. (2019) Is Platelet-Rich Plasma Injection More Effective than Steroid Injection in the Treatment of Chronic Plantar Fasciitis in Achieving Long-Term Relief? Malaysian Orthopaedic Journal, 13, 8-14. &lt;br&gt;https://doi.org/10.5704/MOJ.1911.002</mixed-citation></ref><ref id="hanspub.42049-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Khurana, A., Dhankhar, V., Goel, N., Gupta, R. and Goyal, A. (2020) Comparison of Midterm Results of Platelet Rich Plasma (PRP) versus Steroid for Plantar Fasciitis: A Randomized Control Trial of 118 Patients. Journal of Clinical Orthopaedics &amp; Trauma, 13, 9-14. &lt;br&gt;https://doi.org/10.1016/j.jcot.2020.09.002</mixed-citation></ref><ref id="hanspub.42049-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Peerbooms, J.C., Sluimer, J., Bruijn, D.J. and Gosens, T. (2010) Positive Effect of an Autologous Platelet Concentrate in Lateral Epicondylitis in a Double-Blind Randomized Controlled Trial: Platelet-Rich Plasma versus Corticosteroid Injection with a 1-Year Follow-Up. The American Journal of Sports Medicine, 38, 255-262.  
&lt;br&gt;https://doi.org/10.1177/0363546509355445</mixed-citation></ref><ref id="hanspub.42049-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Shetty, S.H., Dhond, A., Arora, M. and Deore, S. (2018) Platelet-Rich Plasma Has Better Long-Term Results Than Corticosteroids or Placebo for Chronic Plantar Fasciitis: Randomized Control Trial. The Journal of Foot &amp; Ankle Surgery, 58, 42-46. &lt;br&gt;https://doi.org/10.1053/j.jfas.2018.07.006</mixed-citation></ref><ref id="hanspub.42049-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Yang, W., Han, Y., Cao, X., et al. (2017) Platelet-Rich Plasma as a Treatment for Plantar Fasciitis: A Meta-Analysis of Randomized Controlled Trials. Medicine, 96, e8475. &lt;br&gt;https://doi.org/10.1097/MD.0000000000008475</mixed-citation></ref></ref-list></back></article>